Cohen I, Bernheim J, Fishman A, Shapira J, Tepper R, Beyth Y, Cordoba M, Yigael D, Altaras M M
Department of Obstetrics and Gynecology, Sapir Medical Center, Kfar Saba, Israel.
Gynecol Obstet Invest. 1998 Aug;46(2):116-22. doi: 10.1159/000010014.
In order to assess possible ovarian cell potential for interaction with tamoxifen, thus demonstrating possible effects of this agent on the development of ovarian pathologies through growth stimulation and cell proliferation, we measured estrogen receptors (ER) and progesterone receptors (PR) by immunohistochemical method in 16 benign ovarian tumors removed from 11 postmenopausal breast cancer patients treated with tamoxifen (study group). The results were compared with those measured in 7 similar ovarian tumors obtained from 5 similar patients without tamoxifen treatment (control group I), and in 9 similar tumors removed from 9 age-matched postmenopausal women (control group II). There were no significant differences with regard to ER or PR expression between the study group and control group I and II (ER = 18.75, 0.0 and 11%, respectively; PR = 43.75, 28.5 and 44%, respectively; p = NS). There were also no significant statistical differences between the three groups when subdividing the ovarian pathologies according to different histological types. From the results obtained in this study, it seems that tamoxifen probably does not have any direct influence on the ovaries of menopausal breast cancer patients.
为了评估卵巢细胞与他莫昔芬相互作用的潜在可能性，进而证明该药物通过生长刺激和细胞增殖对卵巢病变发展的可能影响，我们采用免疫组织化学方法对11例接受他莫昔芬治疗的绝经后乳腺癌患者切除的16个良性卵巢肿瘤进行了雌激素受体（ER）和孕激素受体（PR）检测（研究组）。将结果与5例未接受他莫昔芬治疗的类似患者切除的7个类似卵巢肿瘤（对照组I）以及9例年龄匹配的绝经后妇女切除的9个类似肿瘤（对照组II）的检测结果进行比较。研究组与对照组I和II之间在ER或PR表达方面无显著差异（ER分别为18.75%、0.0%和11%；PR分别为43.75%、28.5%和44%；p=无统计学意义）。根据不同组织学类型对卵巢病变进行细分时，三组之间也无显著统计学差异。从本研究获得的结果来看，他莫昔芬可能对绝经后乳腺癌患者的卵巢没有任何直接影响。
